Additional file 4: Supplementary Fig. 4. Overall survival analysis of six m&G-related IncRNAs in high and low ezpression groups.

Additional file 1: Figure S1. Surgical procedurefor augmented corticotomy in a subject with severe skeletal Angle Class IIImalocclusion: A) local anesthesia; B) full-Thickness flaps were elevatedon the labial aspect, and areas of fenestration and dehiscene were detected; C) vertical alveolar decortication wasperformed in the interradicular space; D)bone derivative material was placed; E)bioabsorbable collagen membrane was placed to completely cover the graft site; F) flaps were coronally repositionedand sutured in place.

Additional file 1: Figure S1. Surgical procedurefor augmented corticotomy in a subject with severe skeletal Angle Class IIImalocclusion: A) local anesthesia; B) full-Thickness flaps were elevatedon the labial aspect, and areas of fenestration and dehiscene were detected; C) vertical alveolar decortication wasperformed in the interradicular space; D)bone derivative material was placed; E)bioabsorbable collagen membrane was placed to completely cover the graft site; F) flaps were coronally repositionedand sutured in place.

Osteoarthritis (OA) is a rheumatic disease common in the elderly. AGEs are the end products of glycation reactions and play an important role in the development of OA. Etomidate is a general anesthesia-inducing agent recently reported to exert significant anti-inflammatory effects. The present study aims to explore the protective effect of Etomidate against advanced glycation end-products (AGEs)-induced reduction of extracellular matrix gene expression in chondrocytes. In the present study, we found that AGEs significantly reduced...

Cutaneous melanoma (CM) is a malignant and aggressive skin cancer that is the leading cause of skin cancer-related deaths. Increasing evidence shows that immunity plays a vital role in the prognosis of CM. In this study, we developed an immune-related gene pair (IRGP) signature to predict the clinical prognosis of patients with CM. Immune-related genes from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases were selected to construct the IRGPs, and...

Additional file 5: Supplementary Figure S5. The ROC curves for the risk model in the four GCs. A-C The ROC curves of CESC for training (A), validation (B), and total (C) sets. D-F The ROC curves of OV for training (D), valida©n (E), and total (F) sets. G-I The ROC curves of UCEC for training (G), validation (H), and total (I) sets. J-L The ROC curves of UCS for training (J), validation (K), and total...

Additional file 7: Supplementary Figure S7. Clinical value of risk score by independent prognostic analysis. A-H The Univariate Cox regression analysis and Multivariate Cox regression analysis for CESC (A-B), OV (C-D), UCEC (E-F), and UCS G-H.

Additional file 8: Supplementary Figure S8. The Nomogram model based on risk model and clinical features for GCs. A-B The Nomogram (A) and calibration curve (B) for CESC. C-D The Nomogram (C) and calibration curve (D) for OV. (E-F) The Nomo©m (E) and calibration curve (F) for UCEC. G-H The Nomogram (G) and calibration curve (H) for UCS.

Additional file 1: Supplementary Figure S1. Mutation frequency and expression variation of the 76 necroptosis-related genes (NRGs). A-D Mutation frequency of NRGs in patients with CESC (A), OV (B), UCEC (C), and UCS D. The small figure above shows the TMB, the number on the right shows the mutation frequency of each NRG, and the figure on the right shows the proportion of each vari©. E Expression levels of NRGs in four gynecological tumors. The...

Additional file 4: Figure S2. Hazard ratios for long-term all-cause mortality in different subgroups.